Sign In
Section Navigation
Common TitleFLAMINGO
Official Title A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir, DTG (GSK1349572) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naïve Adult Subjects
Phase Phase IIIB
ClinicalTrials.gov NCT01449929
Treatments
Darunavir
Darunavir Prezista

Darunavir

Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)
,
Dolutegravir
Dolutegravir Tivicay

Dolutegravir

Tradename:TivicayOther Names:DTGClass:Integrase Inhibitors (INSTI)
,
Ritonavir
Ritonavir Norvir

Ritonavir

Tradename:NorvirOther Names:RTVClass:Pharmacokinetic Enhancers
Categories Treatment-Naive
Funding
IndustryViiV Healthcare and Shionogi & Co.
References
  • Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222-31.
    [PubMed Abstract]
  • Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17:19490.
    [PubMed Abstract]
  • Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127-36.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.